Did You Know...
...that after Walter Hunt patented the safety pin in 1849, he sold the rights to it for $400?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8158602 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and pept... | 04/17/2012 |
| 8007816 | Yeast-based therapeutic for chronic hepatitis C infection Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be u... | 08/30/2011 |
| 7943149 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and pept... | 05/17/2011 |
| 7632511 | Yeast-based therapeutic for chronic hepatitis C infection Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be u... | 12/15/2009 |
| 7625569 | Yeast-based therapeutic for chronic hepatitis C infection Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be u... | 12/01/2009 |
| 7615228 | Polypeptide fragments of hepatitis E virus, the vaccine comprising said fragments and the diagnostic kits A purified polypeptide comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of a polymer with n monomeric polypeptides, wherein n is an integer from 2-180; to a polypeptide of the present in... | 11/10/2009 |
| 7438920 | Crystals of hepatitis C virus helicase or fragments thereof comprising a helicase binding pocket The invention relates to the X-ray crystal structure of the hepatitis C virus helicase domain. More specifically, the invention relates to crystallized complexes of HCV helicase and an oligonucleotide, to crystallizable compositions of HCV helicase and an oligonucle... | 10/21/2008 |
| 7439347 | Hepatitis C virus non-structural NS3/4A fusion gene Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nuclei... | 10/21/2008 |
| 7429385 | Intracellular production of hepatitis C E1 and E2 truncated polypeptides Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts. ... | 09/30/2008 |
| 7416840 | Replication of hepatitis C virus in non-hepatic epithelial and mouse hepatic cells Cells and cell lines which replicate HCV of non-hepatic human and non human origin are disclosed. Also provided are methods of using such cells and cell lines to identify anti-HCV agents for the treatment of HCV infection. ... | 08/26/2008 |
| 7413741 | HCV E1 comprising specific disulfide bridges The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelop... | 08/19/2008 |
| 7402315 | Hepatitis-C virus type 4, 5 and 6 The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 ... | 07/22/2008 |
| 7378234 | Method for isolating hepatitis C virus peptides Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said... | 05/27/2008 |
| 7371386 | Conserved motif of hepatitis C virus E2/NS1 region The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif with... | 05/13/2008 |
| 7344723 | Self-replicating RNA molecule from hepatitis C virus A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV... | 03/18/2008 |
| 7341726 | Modified HCV peptide immunogens Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, a... | 03/11/2008 |
| 7329408 | Eliciting HCV-specific antibodies Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E... | 02/12/2008 |
| 7326536 | Agents for treatment of HCV and methods of use An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability o... | 02/05/2008 |
| 7319144 | Polynucleotides encoding a multiple epitope fusion antigen for use in an HCV antigen/antibody combination assay The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4a epitope, and an HCV multiple epitope f... | 01/15/2008 |
| 7307066 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and pept... | 12/11/2007 |
| 7285539 | Activation of HCV-specific T cells The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides... | 10/23/2007 |
| 7270820 | CD4+ T-lymphocyte-specific hepatitis C virus epitopes The invention relates to hepatitis C virus epitopes which are CD4+ T-lymphocyte specific, and to vaccines containing these epitopes. ... | 09/18/2007 |
| 7264811 | Purified active HCV NS2/3 protease A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it wit... | 09/04/2007 |
| 7261883 | Vaccines containing ribavirin and methods of use thereof The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribav... | 08/28/2007 |
| 7255864 | Diagnostic reagent for hepatitis C virus infection A diagnostic reagent for hepatitis C virus infection obtained by sensitizing a solid phase with HCV antigen and a conjugated antigen prepared by chemical bonding of HCV antigen and a carrier protein, and a method of diagnosing hepatitis C virus infection, which comp... | 08/14/2007 |
| 7252827 | Conserved motif of hepatitis C virus E2/NS1 region Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/07/2007 |
| 7250166 | Human monoclonal antibodies that bind hepatitis C virus (HCV) E1 The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antib... | 07/31/2007 |
| 7244422 | Vaccines containing ribavirin and methods of use thereof The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribav... | 07/17/2007 |
| 7244715 | Vaccines containing ribavirin and methods of use thereof Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope presen... | 07/17/2007 |
| 7244585 | 3′ Sequence of the GB virus B (GBV-B) genome The present invention relates generally to the fields of biochemistry, molecular biology, and virology. More particularly, it relates to the identification of 259 nucleotides located at the 3′ end of the GB virus B (GBV-B) genome. The invention involves nucleic ac... | 07/17/2007 |
| 7241440 | Vaccines containing ribavirin and methods of use thereof Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope presen... | 07/10/2007 |
| 7238356 | Core-glycosylated HCV envelope proteins The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80% of their N-glycosylation sites are core-glyco... | 07/03/2007 |
| 7226429 | Method for removal of viruses from blood by lectin affinity hemodialysis The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Acc... | 06/05/2007 |
| 7226599 | Diagnostic reagent for hepatitis C virus infection A diagnostic reagent for hepatitis C virus infection obtained by sensitizing a solid phase with HCV antigen and a conjugated antigen prepared by chemical bonding of HCV antigen and a carrier protein, and a method of diagnosing hepatitis C virus infection, which comp... | 06/05/2007 |
| 7226912 | Hepatitis C virus non-structural NS3/4A fusion gene Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nuclei... | 06/05/2007 |
| 7220420 | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core131-140; SEQ ID NO:1), LLALLSCLTV (Core178-187; SEQ ID NO:2), QLRRHIDL... | 05/22/2007 |
| 7208309 | Inhibitor-resistant HCV NS3 protease An inhibitor-resistant HCV NS3 protease is provided which is useful to screen for compounds having therapeutic value against drug resistant HCV strains. In particular, the inhibitor-resistant HCV NS3 protease comprises an amino acid sequence which is mutated in the ... | 04/24/2007 |
| 7201904 | Epitopes of hepatitis C virus The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The composition... | 04/10/2007 |
| 7198892 | Hepatitis-C virus type 4, 5 and 6 The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 ... | 04/03/2007 |
| 7198891 | Hepatitis C virus peptides and uses thereof Novel hepatitis C virus (HCV) polypeptides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets.... | 04/03/2007 |
